Profile data is unavailable for this security.
About the company
Akari Therapeutics, Plc is a late-stage biotechnology company. The Company is developing advanced therapies for autoimmune and inflammatory diseases. Its lead asset, investigational nomacopan, is a bispecific recombinant inhibitor of complement C5 activation and leukotriene B4 (LTB4) activity. Its pipeline includes a Phase 3 clinical trial program investigating nomacopan for pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA). It is conducting a clinical trial of subcutaneous nomacopan for the treatment of HSCT-TMA in pediatrics. The United States Food and Drug Administration (FDA) has granted Rare Pediatric Disease, Orphan Drug, and Fast Track designations to nomacopan for the treatment of pediatric HSCT-TMA. It is also investigating long-acting PASylated-nomacopan (PAS-nomacopan) for treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (dry AMD) in preclinical studies.
- Revenue in USD (TTM)--
- Net income in USD--
- Incorporated2004
- Employees9.00
- LocationAkari Therapeutics PLC22 BOSTON WHARF ROAD, FL 7BOSTON 02210United StatesUSA
- Phone+1 (646) 350-0702
- Fax+1 (646) 843-9352
- Websitehttps://www.akaritx.com/
Mergers & acquisitions
Acquired company | AKTX:NAQ since announced | Transaction value |
---|---|---|
Peak Bio Inc | -15.11% | -- |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Vicapsys Life Sciences Inc | 0.00 | -1.08m | 14.24m | 2.00 | -- | -- | -- | -- | -0.0327 | -0.0327 | 0.00 | -0.0416 | 0.00 | -- | -- | 0.00 | -364.66 | -- | -- | -- | -- | -- | -- | -- | -- | -10.40 | -- | -- | -- | -- | -317.25 | -- | -- | -- |
Mannatech Inc | 127.23m | -1.66m | 14.44m | 213.00 | -- | 1.38 | -- | 0.1135 | -0.899 | -0.899 | 68.07 | 5.54 | 2.77 | 1.93 | 561.74 | 597,342.80 | -3.62 | 4.39 | -9.67 | 9.16 | 78.01 | 77.87 | -1.31 | 1.72 | 0.5584 | -- | 0.1384 | 88.33 | -3.83 | -5.33 | 50.13 | -- | -20.38 | -- |
Pieris Pharmaceuticals Inc | 40.93m | -16.25m | 14.50m | 46.00 | -- | 0.6186 | -- | 0.3544 | -12.74 | -12.74 | 34.05 | 17.76 | 0.7324 | -- | 28.25 | 889,717.40 | -29.09 | -28.41 | -52.98 | -39.69 | -- | -- | -39.71 | -94.61 | -- | -- | 0.00 | -- | 65.28 | 8.03 | 26.25 | -- | -36.82 | -- |
Nexgel Inc | 4.74m | -3.20m | 14.51m | 19.00 | -- | 3.03 | -- | 3.06 | -0.5535 | -0.5535 | 0.8208 | 0.7688 | 0.4428 | 3.24 | 8.46 | 249,263.20 | -30.72 | -44.61 | -39.92 | -56.19 | 20.14 | 5.02 | -69.38 | -180.98 | 1.41 | -- | 0.1819 | -- | 99.66 | 13.06 | 33.48 | -- | -- | -- |
Oncotelic Therapeutics Inc | 70.00k | -7.79m | 14.63m | 22.00 | -- | 1.24 | -- | 208.98 | -0.0197 | -0.0197 | 0.0002 | 0.0296 | 0.0021 | -- | 3.61 | 3,181.82 | -24.46 | -25.03 | -49.25 | -48.76 | -- | -- | -11,536.00 | -1,692.93 | -- | -0.4696 | 0.5341 | -- | -- | -- | -255.12 | -- | -- | -- |
Edesa Biotech Inc | 0.00 | -7.25m | 14.70m | 16.00 | -- | 3.40 | -- | -- | -2.37 | -2.37 | 0.00 | 1.34 | 0.00 | -- | -- | 0.00 | -84.50 | -- | -107.87 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 52.28 | -- | -- | -- |
Trinity Biotech plc (ADR) | 56.83m | -36.87m | 14.77m | 380.00 | -- | -- | -- | 0.2598 | -4.82 | -3.14 | 7.42 | -15.67 | 0.7501 | 1.76 | 3.83 | 149,557.90 | -48.66 | -20.30 | -61.88 | -29.54 | 34.22 | 39.92 | -64.87 | -29.86 | 1.27 | -1.61 | 1.55 | -- | -9.10 | -10.15 | 15.41 | -- | -31.08 | -- |
CERo Therapeutics Holdings Inc | 0.00 | -2.54m | 14.91m | 8.00 | -- | -- | -- | -- | -0.3796 | -0.3796 | 0.00 | -0.9226 | 0.00 | -- | -- | 0.00 | -9.96 | -- | -33.80 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -279.82 | -- | -- | -- |
Akari Therapeutics PLC (ADR) | -100.00bn | -100.00bn | 15.13m | 9.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -149.95 | -- | -435.18 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 43.61 | -- | -- | -- |
Sunshine Biopharma Inc | 24.09m | -4.51m | 15.20m | 44.00 | -- | 0.0106 | -- | 0.6309 | -19.07 | -19.07 | 99.47 | 75.68 | 0.8515 | 3.49 | 10.79 | 547,563.40 | -15.92 | -101.52 | -20.43 | -137.04 | 34.61 | 35.47 | -18.70 | -165.33 | 3.45 | -- | 0.00 | -- | 454.42 | -- | 83.15 | -- | 110.99 | -- |
Microbot Medical Inc | 0.00 | -10.26m | 15.55m | 22.00 | -- | 2.52 | -- | -- | -0.8926 | -0.8926 | 0.00 | 0.4283 | 0.00 | -- | -- | 0.00 | -151.13 | -53.28 | -183.85 | -62.65 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 18.44 | -- | -31.76 | -- |
Allied Corp | 21.51k | -9.00m | 15.64m | -- | -- | -- | -- | 727.09 | -0.0915 | -0.0915 | 0.0002 | -0.0711 | 0.0051 | 1.65 | 0.1441 | -- | -214.39 | -- | -- | -- | -6,919.57 | -- | -41,861.41 | -- | 0.0333 | -31.86 | -- | -- | -56.46 | -- | 31.30 | -- | -- | -- |
Flora Growth Corp | 74.78m | -47.58m | 16.02m | 97.00 | -- | 3.58 | -- | 0.2142 | -6.53 | -7.77 | 9.20 | 0.3494 | 1.48 | 5.99 | 23.05 | 770,958.80 | -92.50 | -- | -140.01 | -- | 21.72 | -- | -62.66 | -- | 0.6481 | -- | 0.4952 | -- | 127.75 | -- | -1.87 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Omnia Family Wealth LLCas of 31 Mar 2024 | 87.63k | 1.11% |
Sabby Management LLCas of 31 Mar 2024 | 48.49k | 0.61% |
Cerity Partners LLCas of 31 Mar 2024 | 23.64k | 0.30% |
Renaissance Technologies LLCas of 31 Mar 2024 | 14.77k | 0.19% |
BG Fund Management Luxembourg SAas of 31 Dec 2023 | 6.11k | 0.08% |
Bank of America, NA (Private Banking)as of 31 Mar 2024 | 150.00 | 0.00% |
Truvestments Capital LLCas of 31 Mar 2024 | 50.00 | 0.00% |
Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Mar 2024 | 6.00 | 0.00% |
Cornerstone Planning Group LLCas of 31 Mar 2024 | 5.00 | 0.00% |
Tower Research Capital LLCas of 31 Mar 2024 | 0.00 | 0.00% |